Replies to post #739 on Rosetta Genomics Ltd (ROSGQ)

[bullmarket2222]

Here is another study that ROSG *should* publish the results of soon. I would guess it'll be used to get more insurance coverage.

The study should have been completed sometime last month.

From clinicaltrials.gov:


Official Title: An Exploratory Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP) in Israel

Further study details as provided by Teva Pharmaceutical Industries:

Primary Outcome Measures: cost-effectiveness [ Time Frame: 18 months ] [ Designated as safety issue: No

To compare the cost-effectiveness of miRview™ mets test with conventional work-up in cancer of unknown primary (CUP) patients, by comparing total cost and time of the diagnostic process (including hospitalization time) from day 1 of the study to the decision on treatment program


Secondary Outcome Measures: compare the diagnostic performance [ Time Frame: 18 months ] [ Designated as safety issue: No ]

1) Evaluating the miRview™ mets results based on the clinical and
pathological work-up in all patients (retrospectively).
2) Evaluating the concordance between miRview™ mets result and the
diagnosis obtained by the standard work-up process.
3) Comparing the response to treatment between study groups.
4) Comparing overall survival between study groups


Biospecimen Retention: Samples Without DNA
Formalin Fixed Paraffin Embedded tumor tissue

Estimated Enrollment: 60
Study Start Date: May 2010
Estimated Study Completion Date: April 2012
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)


http://clinicaltrials.gov/ct2/show/NCT01...